



李氏大藥廠

Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司

Lee's Pharmaceutical's Profit Surged 86% in 1Q2009
Achieved Nine Consecutive Quarters of Double Digit Growth

Financial Highlight (For the three months ended 31 March)			
	2009 (HK\$'000)	2008 (HK\$'000)	Change (%)
Turnover	33,035	22,513	+46.7%
Gross Profit	23,602	15,918	+48.3%
Gross Profit Margin	71.4%	70.7%	+0.7%pt
Profit Attributable to Shareholders	7,802	4,193	+86.1%
Earnings per Share (Basic)	HK1.88cents	HK1.01cents	+86.1%

[14 May 2009 - Hong Kong] Lee's Pharmaceutical Holdings Limited ("Lee's Pharmaceutical" or the "Group", Stock Code: 8221), today announced its unaudited consolidated results for the three months ended 31 March 2009 (the "period under review").

As an integrated research-driven and market-oriented pharmaceutical group in China, **Lee's Pharmaceutical** continued to benefit from the increasing sales of all products especially Iron Proteinsuccinylate Oral Solution which achieved the highest increment of 288%. During the period, the Group achieved a revenue of approximately HK\$33.0 million, representing a 46.7% growth compared with the same period of last year.

The Group recorded solid results during the period under review, keeping pace with the growth momentum of 2008. Gross profit increased to approximately HK\$23.6 million and profit attributable to shareholders surged by 86.1% to approximately HK\$ 7.8 million. During the period under review, the gross profit margin of the Group increased from 70.7 % in 2008 to 71.4% in 2009. This improvement was mainly due to the decrease in cost of Carnitene®.

In March 2009, the Group successfully concluded a license agreement with a premium Japanese pharmaceutical company, Nippon Shinyaku Co., Ltd., for the pharmaceutical product containing antibacterial agent "Prulifloxacin" for the treatment of urinary tract infections and respiratory tract infections.

~Cont'd~



Commenting on the Group's outstanding performance, Dr. Benjamin Li, CEO of the Group said, "Riding on the growth momentum of 2008, the Group was able to achieve satisfactory results during the period under review. The Group entered into cooperation with Nippon Shinyaku Co., Ltd. which represents a significant breakthrough in the Group's corporate development. With our renowned brand and abundant experiences in China, Lee's Pharmaceutical becomes a preferred partner in China for the worldwide research-based pharmaceutical companies, making it possible for us to further strengthen our pipeline and maintain our rapid growth."

Dr Li continued, "Both Veloderm® and Challenger balloon, our license-in products, are entering the final stage of registration. Their import licenses are expected to be granted in the coming quarters. These products will offer new growth opportunities for us and enhance our sustainability. Looking ahead, we are confident that the sales of all existing products will sustain in current rapid growth trend, bringing desirable returns to our shareholders."

~End~

Information about Lee's Pharmaceutical Holdings Limited

Lee's Pharmaceutical Holdings Limited, a biopharmaceutical company, was successfully listed on the Growth Enterprise Market (GEM) of the Stock Exchange of Hong Kong Limited in 2002, with over 14 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing and sales and marketing in China with global perspective and it currently markets five products in China. The Group focuses on many different areas such as cardiovascular diseases, dermatology, oncology, gynecology and others with more than 20 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US and European companies.

Issued by Porda International (Finance) P.R. Company Limited for and on behalf of **Lee's Pharmaceutical Holdings Limited**. For further information, please contact:

Porda International (Finance) P.R. Company Limited

Keely Chan	keely.chan@pordafinance.com.hk	Tel: (852) 3150 6760 / (852) 9770 2950
Alman Loong	alman.loong@pordafinance.com.hk	Tel: (852) 3150 6731 / (852) 9107 8225
Liz Yip	liz.yip@pordafinance.com.hk	Tel: (852) 3150 6739 / (852) 9497 1685
Fax: (852) 3150 6728		

